Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

NCR graphs - Age specific incidence rates

- All cancer age-specific incidence rates, including non-melanoma skin cancer, males, Lebanon, 2005, 2010, 2015
- All cancer age-specific incidence rates, including non-melanoma skin cancer, females, Lebanon, 2005, 2010, 2015

- All cancer age-specific incidence rates, excluding non-melanoma skin cancer, males, Lebanon, 2005, 2010, 2015
- All cancer age-specific incidence rates, excluding non-melanoma skin cancer, females, Lebanon, 2005, 2010, 2015

- Oesophagus cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Oesophagus cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Estomac cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Estomac cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Colo-rectal cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Colo-rectal cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Liver cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Liver cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Gallbladder and extrahepatic bilary tract cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Gallbladder and extrahepatic bilary tract cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Pancreas cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Pancreas cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Larynx cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Larynx cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Trachea-bronchus-lung cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Trachea-bronchus-lung cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Bone cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Bone cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Melanoma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Melanoma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Non-melanoma skin cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Non-melanoma skin cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Breast cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Breast cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Col uteri cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015
- Corpus uteri cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015
- Ovary cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Prostate cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Testis cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015

- Kidney cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Kidney cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Bladder cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Bladder cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Brain and central nervous system cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Brain and central nervous system cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Thyroid cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Thyroid cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Hodgkin's lymphoma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Hodgkin's lymphoma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Non-Hodgkin lymphoma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Non-Hodgkin lymphoma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Multiple Myeloma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Multiple Myeloma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Lymphoid leukemia age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Lymphoid leukemia age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Myeloid leukemia age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Myeloid leukemia age-specific incidence rates, females, Lebanon, 2005, 2010, 2015
 
    ...
    47
    ...
ATC Name B/G Ingredients Dosage Form Price
L01XA03 OXALIPLATINO GP PHARM G Oxaliplatin - 50mg 50mg Injectable lyophilised powder for solution 2,956,454 L.L
L01XA03 OXALTIE G Oxaliplatin - 50mg 50mg Injectable lyophilised powder for solution 2,957,797 L.L
L01XG01 VELCADE B Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder for solution 23,616,000 L.L
L01XG01 BORTEZOMIB NEAPOLIS G Bortezomib - 3.5mg 3.5mg Injectable lyophilised powder for solution 14,169,600 L.L
R03DX05 XOLAIR BioTech Omalizumab - 150mg 150mg Injectable lyophilised powder for solution+diluent 54,613,625 L.L
L02AE04 DECAPEPTYL B Triptorelin - 0.1mg 0.1mg Injectable lyophilised powder for solution+diluent 2,366,507 L.L
B02BD02 XYNTHA BioTech Moroctocog alfa - 500IU 500IU Injectable lyophilised powder for solution+diluent L.L
B02BD02 BERIATE BioHuman Coagulation Factor VIII - 250IU 250IU Injectable lyophilised powder for solution+diluent 14,098,526 L.L
B02BD02 OCTANATE BioHuman Coagulation Factor VIII - 250IU 250IU Injectable lyophilised powder for solution+diluent 13,247,110 L.L
B02BD02 BERIATE BioHuman Coagulation Factor VIII - 500IU 500IU Injectable lyophilised powder for solution+diluent 28,437,886 L.L
B02BD02 OCTANATE BioHuman Coagulation Factor VIII - 500IU 500IU Injectable lyophilised powder for solution+diluent 26,495,478 L.L
B02BD02 OCTANATE BioHuman Coagulation Factor VIII - 1,000IU 1,000IU Injectable lyophilised powder for solution+diluent 46,817,511 L.L
B02BD02 XYNTHA BioTech Moroctocog alfa - 500IU 500IU Injectable lyophilised powder for solution+diluent 23,067,288 L.L
N03AG01 DEPAKINE B Sodium Valproate - 400mg 400mg Injectable lyophilised powder for solution+diluent 450,187 L.L
B02BD04 IMMUNINE BioHuman Plasma coagulation factor IX, human - 600IU 600IU Injectable lyophilised powder for solution+diluent 20,506,214 L.L
B02BD06 HAEMATE P BioHuman Von Willebrand Factor - 1200IU, Blood Coagulation Factor VIII - 500IU Injectable lyophilised powder for solution+diluent 35,032,787 L.L
J07AH08 NIMENRIX B Polysaccharide of Neisseria meningitidis (serogroups A, C, Y and W-135) conjugated - 5mcg/0.5ml, Tetanus toxoid carrier protein - 44mcg/0.5ml Injectable lyophilised powder for solution+diluent 4,483,059 L.L
J07BD52 PRIORIX B Rubella virus live attenuated - ?10³ CCID50, Mumps virus live attenuated - ?103.7 CCID50, Measles virus live attenuated - ?10³ CCID50 Injectable lyophilised powder for solution+diluent 1,142,266 L.L
J07BK01 VARILRIX + SOLVENT IN SYRINGE B Varicella virus, live attenuated - ?1033 PFU ?1033 PFU Injectable lyophilised powder for solution+diluent 3,473,833 L.L
J01DD01 CEFOTAX G Cefotaxime (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 217,702 L.L
J01DD01 STOPAREN G Cefotaxime (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 213,671 L.L
H01AB01 THYROGEN BioHuman Thyrotropin alfa - 0.9mg 0.9mg Injectable lyophilised powder for solution+diluent 65,558,997 L.L
J01DD04 ROCEPHIN IV B Ceftriaxone (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 757,927 L.L
J01DD04 ROCEPHIN IM B Ceftriaxone (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 731,050 L.L
J01DD04 CEFAXONE IV G Ceftriaxone - 1g 1g Injectable lyophilised powder for solution+diluent 403,153 L.L
J01XA02 TARGOCID B Teicoplanin - 400mg 400mg Injectable lyophilised powder for solution+diluent 1,331,748 L.L
J01XA02 TARGOCID B Teicoplanin - 200mg 200mg Injectable lyophilised powder for solution+diluent 714,924 L.L
H01CC02 CETROTIDE B Cetrorelix (acetate) - 0.25mg 0.25mg Injectable lyophilised powder for solution+diluent 3,420,079 L.L
H01CC02 CETROTIDE B Cetrorelix (acetate) - 0.25mg 0.25mg Injectable lyophilised powder for solution+diluent 21,354,452 L.L
H01CC02 CETROTIDE B Cetrorelix (acetate) - 0.25mg 0.25mg Injectable lyophilised powder for solution+diluent 21,354,452 L.L
    ...
    47
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025